Last reviewed · How we verify
AZD0292
AZD0292 is a small molecule inhibitor of the PI3K delta subunit.
AZD0292 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsed or refractory chronic lymphocytic leukemia, Relapsed or refractory non-Hodgkin lymphoma.
At a glance
| Generic name | AZD0292 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PI3K delta subunit, AZD0292 is thought to modulate the immune response and potentially treat various conditions.
Approved indications
- Relapsed or refractory chronic lymphocytic leukemia
- Relapsed or refractory non-Hodgkin lymphoma
Common side effects
- Musculoskeletal pain
- Diarrhea
- Nausea
- Fatigue
- Cough
Key clinical trials
- A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization (PHASE2)
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese Participants (PHASE1)
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD0292 CI brief — competitive landscape report
- AZD0292 updates RSS · CI watch RSS
- AstraZeneca portfolio CI